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Abstract
Background: Decisive information on the parameters involved in cognitive impairment in patients with chronic
heart failure is as yet lacking. Our aim was to determine the functional and psychosocial variables related with
cognitive impairment using the mini-mental-state examination (MMSE) with age-and education-corrected scores.
Methods: A cohort study of chronic heart failure patients included in an integrated multidisciplinary hospital/
primary care program. The MMSE (corrected for age and education in the Spanish population) was administered at
enrolment in the program. Analyses were performed in 525 patients. Demographic and clinical variables were
collected. Comprehensive assessment included depression (Yesavage), family function (family APGAR), social
network (Duke), dependence (Barthel Index), frailty (Barber), and comorbidities. Univariate and multivariate logistic
regression were performed to determine the predictors of cognitive impairment.
Results: Cognitive impairment affected 145 patients (27.6 %). Explanatory factors were gender (OR: 2.77 (1.75–4.39)
p < 0.001), ischemic etiology (OR: 1.99 (1.25–3.17) p = 0.004), frailty (OR: 1.58 (0.99 to 2.50, p =0.050), albumin > 3.5
(OR: 0.59 (0.35–0.99) p = 0.048), and beta-blocker treatment (OR: 0.36 (0.17 to 0.76, p = 0.007)). No association was
found between cognitive impairment and social support or family function.
Conclusion: The observed prevalence of cognitive impairment using MMSE corrected scores was 27.6 %. A global
approach in the management of these patients is needed, especially focusing on women and patients with frailty,
low albumin levels, and ischemic aetiology heart failure.
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Abbreviations: CHF, Chronic heart failure; CI, Cognitive impairment; LVEF, Left ventricular ejection fraction;
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Background
Cognitive impairment (CI) is particularly common in pa-
tients with chronic heart failure (CHF) and has been
associated with an increased mortality rate in hospital
admissions and worse clinical outcomes [1]. Neverthe-
less, it is still uncertain when CI should be assessed in
common clinical practice, the instruments that should
be employed for primary evaluation, and which patients
should be included in a more extensive neuropsycho-
logical diagnostic battery. Despite interest in the global
assessment of CHF there is as yet no decisive informa-
tion on which factors play a role when deciding whether
routine cognition screening in clinical practice would be
helpful for an individual patient.
The prevalence of CI depends on the test used and
varies widely among studies, ranging from less than
30 % to more than 80 % [2–7]. As cognitive tests are
age-and education sensitive [8] the use of a validated
screening test in our population would provide valuable
information on CI prevalence. The Mini Mental State
Examination (MMSE) is a widely used instrument to
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evaluate cognitive function in CHF patients [9, 10]. It
determines global cognitive impairment and is more
commonly employed in clinical practice than complex
neuropsychological batteries [4, 11].
The present study aims to assess CI prevalence with
the MMSE, and identify clinical, psychological, social,
family, and frailty-related factors, in a large sample of
CHF patients.
Methods
From 2005 to 2010, 805 consecutive patients were en-
rolled as a cohort of non-institutionalized patients referred
to hospital-primary care integrated multidisciplinary nurse
led heart failure program [12]. We present here the base-
line assessment. Assessment was conducted at the time of
patient inclusion in the heart failure program. Once diag-
nosis was confirmed on an ambulatory basis, the patient
was invited to be included in the heart failure registry.
Then, clinical and analytical data were collected, and psy-
chosocial evaluations were performed by hospital nurses
specifically trained in heart failure. The evaluation was
carried out in a single session, with the cognitive test ad-
ministered first. The study was conducted in accordance
with the Declaration of Helsinki. The study protocol was
approved by the local committee of ethics for clinical
research and all patients gave written informed consent
after recruitment. For inclusion in the study, patients had
to be in a stable condition and with a CHF diagnosis of
either reduced or preserved ejection fraction, according to
the European Society of Cardiology diagnostic criteria
[13]. Additionally, inclusion in the study required that
patients were able to undergo neuropsychological testing
and could communicate adequately in order to follow
the tests instructions by themselves. Exclusion criteria
for the study were: significant primary valvular disease,
hemoglobin levels < 8.5 g/dL, clinical signs of fluid
overload, pericardial disease, restrictive cardiomyop-
athy, hypertrophic cardiomyopathy, active malignancy
and chronic liver disease. Patients with serious psychi-
atric illness, unstable CHF, overt cognitive impairment
which impeded psychosocial assessment; and those
suffering from extra-cardiac disease with a life expect-
ancy of less than 1 year were also excluded. No experi-
mental intervention was performed.
Clinical variables
At recruitment, peripheral blood samples were taken to
measure the usual biological variables needed to per-
form initial evaluation in heart failure patients. Clinical
and demographic information assessed included CHF
etiology; New York Heart Association (NYHA) functional
class, heart rate, pro-brain natriuretic peptide (Nt proBNP),
blood pressure, current medical therapy and the most re-
cent left ventricular ejection fraction (LVEF) evaluation.
Recorded comorbidities were current diabetes mellitus,
history of stroke or cerebrovascular disease, peripheral ar-
terial disease, chronic kidney disease, anemia, and chronic
obstructive pulmonary disease. Once CHF diagnosis had
been confirmed on an outpatient basis the patient was
invited to be included in the heart failure registry. Clinical
and analytical data were then collected, and evalua-
tions were performed by cardiology nurses trained in
heart failure management.
Cognitive functions
All the patients who agreed to participate underwent a
comprehensive psycho-social assessment. From those
invited 122 had an incomplete evaluation and were ex-
cluded. The MMSEwas completed at baseline in all
the 683 remaining patients, either by a neuropsycholo-
gist or a specialized nurse who had received specific
training. Of those tested, 158 had not education recorded
and were excluded. MMSE [14] Spanish validated version
(30 items, cognitive impairment scores ≤ 24) [15]) with
scores adjusted by age and education was finally calculated
in 525 patients (Fig. 1). The MMSE measures overall
cognitive impairment, it includes brief assessments of
memory, language, praxis, and orientation and it is
regarded as the gold standard in cognitive impairment de-
tection [16]. It has been used in heart failure patients [5],
it takes approximately 10 min to administer, and It has
been found predictor of hospital readmission [3, 15, 17].
Age and education corrected scores were calculated
following Blesa MMSE validation in Spanish popula-
tion. These corrections add or subtract up to 2 points
depending on age bands and education level (Table 1).
Other corrections have been proposed but external
validity of Blesa correction is particularly appropriate
as it was carried out in our area. No experimental
intervention was performed.
Fig. 1 Patient flow showing exclusion criteria
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Psycho-social evaluation
Education was assessed as categorical variable: illiter-
ates, elementary education (4 years of education), high
school (up to 9 years), and college (more than 10 years).
We recorded marital status, living with a partner, self-
administration of medication, and the need for a caregiver.
Dependency was measured by the validated Spanish
version of the Barthel test [18] for basic daily activ-
ities, in its Spanish validation version; with scores ranging
from 0 to 100, those <90indicate dependency. Family func-
tion was recorded following The Family APGAR question-
naire in its Spanish form [19], the scale can range from 0
to 10, < 7 represents family dysfunction.
Depression was screened with the short form of the
Spanish validated version [20] of the Yesavage Geriatric
Depression Scale [21]. Scores > 4 indicate depression.
Social support is positively associated with medication
compliance [22–25]. We used The Duke-UNC Func-
tional Social Support Questionnaire [26], an eight-item
3Likert scale in which the higher the average score, the
greater the perceived social support. A cut-off of 32 has
been proposed in its Spanish version.
Frailty was screened with the self-reported Barber
questionnaire [27] in its Spanish validated version [28].
This questionnaire assesses functional status, psycho-
social functioning, neurosensory deficits, self-reported
health, social support, and previous year hospital admis-
sions. The three major domains in frailty [29]-physical,
psychological and social-are represented. It is a 9-item
screening tool, easy to understand and self-administer,
which identifies individuals who may be at risk of
dependency. Any positive item indicates frailty. A cutoff
of 2 was applied to increase the positive predictive value
of the test since most patients had a recent admission in
the previous year.
Statistical methods
Demographic and clinical data were summarized with
basic descriptive statistics in the total cohort. For
quantitative variables arithmetic mean (± standard
deviation) or median (interquartile range) were calcu-
lated as appropriate, and P values derived from a two-
sample t-test (U-Mann–Whitney tests were used for
skewed data). For qualitative variables, percentages
within specified groups were calculated and P values
were derived using Chi [2] tests. All the tests were two-
sided; differences were considered significant at the p < 0.05
level.
The following clinical variables were dichotomized be-
fore entering the linear regression model: age over 65/
below 65, higher education meaning more than 10 years
versus less than 10 years of formal education, mild
NYHA class I, II versus advanced NYHA III, IV, pre-
served left ventricle ejection fraction vs. impaired, heart
rate over 70 versus HR below 70 as heart rate over 70 is
a marker of disease severity and mortality predictor [30].
albumin <3,5 yes/no. NtproBNP was dichotomized over
the median as multiple factors influence its values
beyond the predictive cut off 1000. Logistic regression
models (enter) were generated to explore the relationships
between dichotomous and clinical variables. Clinical, func-
tional and biochemical values, echocardiography and co-
existing diseases were used as explanatory variables.
Univariate analysis was composed of the comparison of
cognitive impairment/cognitive normal according to
MMSE age-education cut-off scores. Differences be-
tween the cognitively normal/impaired groups were
calculated using logistic regression model one-to one
analyses.
Variables that showed statistical significance (p <0.10)
in the univariate analysis were included in the multivar-
iable logistic regression (enter method) using MMSE
age-and education-corrected scores as the main vari-
able. Three logistic regression models (enter) were com-
pleted. Model one included only the clinical factors,
model two included psychosocial factors and model three
both clinical and psychosocial factors. Results were pre-
sented as odds ratios (OR) with 95 % confidence intervals
(CI). The Hosmer-Lemeshow chi-square test was used to
assess the models’ goodness-of-fit. Various models were
developed, including several combinations of adjustment
variables. Co-linearity problems were not observed as the
change of the standard coefficient errors was not relevant
in terms of loss of statistical significance.
All models were carried out in the final patient sample
(n = 525). SPSS® version 13.0 (IBM, Armonk, NY, USA)
was employed for statistical analyses.
Results
Cognitive impairment and clinical markers
Of the total sample size (n = 525), 145 participants
(27.6 %) were affected by CI as determined by MMSE
age-and education-corrected scores. There were no
differences between participants and non-participants
with respect to gender, education level, marital status,
CHF etiology, natriuretic peptide levels, ventricular
function, cardiovascular risk factors, reactive depres-
sion, comorbidity, or need of a caregiver. The former
Table 1 Correction table of MMSE by age and education. Points
added/subtracted from MMSE
Age
Education (years) ≤50 51–75 >75
≤8 0 +1 +2
9–17 −1 0 +1
>17 −2 −1 0
Based on Blesa [15]
González-Moneo et al. BMC Cardiovascular Disorders  (2016) 16:163 Page 3 of 10
had hypercholesterolemia less frequently (45, 38.5 % vs.
360, 54.1 %, p = 0.001) and were more often included in
the advanced NYHA functional class (59, 58.4 % vs. 295,
44.3 % p = 0.005).
The clinically relevant affected MMSE areas in CHF
patients with CI were orientation, attention, recall, lan-
guage, and copying. The worst scores were found in
NHYA advanced stages, and only registration was stable
in the functional class (Fig. 2). Markers of disease sever-
ity such as higher levels of Nt pro-BNP, heart rate > 70,
and advanced NHYA functional class were related to CI
(Table 2). Mean albumin levels were lower in patients
with CI, with a 3.5 cutoff being the most significant; al-
bumin levels > 3.5 were protective, in contrast, albumin
levels < 3.5 were related to CI (Fig. 3). Ischemic and
hypertensive patients were more impaired than those
with heart failure from other causes. Beta-blocker pre-
scription provided a significant reduction in CI (RR: 0.35
(IC95%, 0.18–0.66)) whilst non-use showed an inverse
relationship (RR 1.94 (IC 95 %, 1.37–2.74)). No associ-
ation was found between CI and other drugs commonly
used such as angiotensin-converting-enzyme inhibitor
and angiotensin receptor blockers
Gender and education
Patients with CHF and CI impairment were older, had less
than 9 years of formal education, and were predominantly
female. CI was less common in patients with higher edu-
cation (defined as more than 9 years of formal education)
(Table 2). More men had completed higher education
than women [153 (47.8 %) vs. 46 (22.4 %) p < 0.001]. CI
was more common in women after adjusting by education
and NHYA class although the relationship could be mod-
erated by ischemic etiology: CI was more likely in women
with ischemic etiology heart failure [OR: 2.303, (95 % IC
1.204–4.405, p < 0.001)].
Co-morbidities
We observed a relationship between CI and mean glom-
erular flow. CI was also more frequent in patients with
chronic kidney disease, diabetes, and peripheral vascular
disease. Cerebrovascular disease almost reached signifi-
cance (Table 2) and was included in the final model.
Anemia was more common in the CI group but not
significant (p = 0 .078). Pulmonary obstructive disease
was not related with CI in our sample.
Psychosocial factors
Cognitively impaired patients were more likely in need
of a caregiver, and not able to administer treatment by
themselves. Decreased CI was related to greater patient
autonomy for the management of treatment (Table 3).
Depressive symptoms were more frequent in cogni-
tively impaired patients, almost reaching significance
Fig. 2 Cognitive impairment in heart failure patients according to Mini-Mental-State Examination sub-items median scores in initial and advanced
NHYA functional class. Statistical significance: (Mann-Whinney U): Orientation: p <0.001, registration: p =0.126, Attention: p =0.004, Recall: p =0.168,
Language and copying: p = 0.001. NHYA: New York Heart Association
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(p = 0.064). Lack of social support measured by Duke’s
questionnaire was minimal in our sample and non-
significant. Less than 15 % of the patients lived in a dys-
functional family, and this factor was un-related to CI.
Multivariate analyses
Adjusting for the significant factors identified in the un-
varied analyses, we performed three different multivari-
ate binary logistic regression models to evaluate (i)
clinical factors, (ii) functional ones, and (iii) both. Age-
and education-corrected MMSE scores were employed
as the main variable in all 525 patients (Table 4). In a
clinical model (model 1), patients with overt CI were
significantly more likely to be women, and have ischemic
etiology and low albumin levels. They were less probably
receiving beta-blocker treatment. Dependency and
frailty presented a significant association with CI in
the functional model (model 2). The presumed association
between CI and self-reported frailty almost reached
statistical significance after clinical variables were
included (p = 0.050) (model 3). Gender and ischemic
etiology prevailed in the explanatory model when all
variables were added. In addition, albumin levels > 3.5
and beta-blocker treatment emerged as potentially pro-
tective CI factors.
Discussion
Cognitive impairment
In this single center study we have found that cognitive
impairment determined by age-and education-corrected
MMSE scores affected 145 of 525 patients (27.6 %),
which is consistent with other studies that used this test
in patients with heart failure [31]. Nevertheless, other
screening methods employed in this type of patients
have obtained different figures, as CI prevalence varies
according to the test used. Lately, MOCA has emerged
as a possible screening tool although it does not take
into account the potential false positives that can pro-
vide prevalence figures up to 80 % [1]. In a comparative
study of the MOCA and MMSE in a small sample of
Table 2 Demographics and baseline characteristics of Chronic Heart Failure patients according to cognitive function (CI) n = 525
Overall Normal Cognitive impairment n p value
Demographics, n% 525 380 (72) 145 (28) 525
Age, years, mean (SD) 71 (11) 70 (11) 75 (9) 525 <0.001
Female gender n (%) 205 (39) 126 (33) 79 (55) 525 <0.001
NYHA class n% (I, II / III, IV) 300 (59) / 211 (41) 229 (62) / 139 (38) 71 (50) / 72 (50) 511 0.007
Heart rate > =70, bpm, n (%) 304 (59) 210 (56) 94 (66) 515 0.034
SBP, mean (SD) 126 (22) 126 (23) 124 (21) 517 0.324
Preserved LVEF %, mean (SD) 180 (34) 131 (34) 49 (34) 525 0.484
Aetiology of CHF, n% 382 (73) 268 (71) 114 (79) 520 0.042
Hypertension n% 412 (79) 295 (79) 114 (79) 520 0.459
Diabetes n% 239 (47) 162 (44) 77 (54) 511 0.023
Peripheral artery disease n% 99 (19) 63 (17) 36 (25) 521 0.020
CKD 286 (55) 195 (52) 91 (63) 523 0.014
Anaemia n% 176 (33) 120 (32) 56 (39) 525 0.078
Cerebrovascular disease n% 62 (12) 40 (11) 22 (15) 521 0.089
COPD n% 114 (22) 79 (21) 35 (24) 517 0.239
ACEI or ARBs n% 426 (82) 311 (83) 115 (80) 519 0.243
Betablockers n% 482 (92) 358 (95) 124 (86) 522 0.001
MRA n% 228 (44) 167 (44) 61 (42) 521 0.383
Nt-pro BNP n% 248 (48) 169 (45) 79 (56) 515 0.014
Albumin mean (SD) 4 (0) 4 (0) 3.6 (0) 501 <0.001
Albumin < 3.5 97 (19) 57 (16) 40 (28) 501 0.002
eGFR mean (SD) 59 (22) 60 (23) 55 (21) 523 <0.017
Cognitive impairment defined by age and education corrected MMSE scores. Data are presented as means ± standard deviation, medians (with interquartil range)
or numbers (with percentages) where appropriate. Percentages are rounded. NYHA class: New York Heart Association functional class: LVEF: left ventricle ejection
fraction. SBP: systolic blood pressure. CHF: chronic heart failure. Aetiology of CHF: patients with ischemic and hypertensive aetiology versus other causes. CKD:
Chronic kidney Disease: eGFR < 60 mL/min/1.73 m2. Anaemia was defined as haemoglobin level <12 g/dL in women and <13 gr/dL in men. Cerebrovascular
disease defined as. COPD: chronic obstructive pulmonary disease defined following GOLD (Global Initiative of Chronic Obstructive Lung disease) Guidelines.
ACEI:angiotensin-converting-enzyme inhibitor. ARBs: Angiotensin II receptor blockers. MRA: Mineral corticoid receptor blockers. Nt-proBNP: N-terminal pro Brain
Natriuretic Peptide over 1512 (median scores). eGFR: estimated glomerular filtration rate
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patients, Athilingam et al. (Heart & Lung 2011) found
no relationship between clinical parameters of cardiac
function and the high rate of CI detected by the
MOCA (54 %).
Howkins et al [4] compared the MOCA and MMSE
against a neuropsychological battery in 106 patients. They
reported adequate sensitivity for both tests (64–70 %)
although in terms of specificity, the MMSE was slightly
better than the MOCA (70 % vs. 64 %, respectively). This
difference in specificity had already been highlighted by
Lees et al. [32] in patients with vascular CI.
Both the MOCA and MMSE are clearly influenced
by age and education, the former is considered more
appropriate in populations with more than 12 years
of schooling. The characteristics of the MoCA subtests,
which include several complex executive demanding tasks,
make it more prone to false positives when it comes to
detect cognitive impairment in low educated subjects,
making necessary extreme adjustments (up to 4 points in
Spanish-speaking individuals; Zhou 2015) [33]. In this
regard, we think that MMSE is still useful for its use in
low-educated subjects. As a consequence, we employed a
validated Spanish MMSE adjusted for age and education
which had not only good internal validity but also excel-
lent external validity as it was validated in our area.
Other methods use brief screening tools evaluating only
memory, such as the Memory Impairment Screening test
(MIS) which in the EFICARE study resulted in 46 % preva-
lence [34], whilst the MMSE implements more varied sub-
domains [5–7, 35, 36]. The fact that the prevalence found
depends on the test used [5, 37, 38] underlines the import-
ance of using tests validated for the population in focus,
with appropriately age-and-education corrected versions.
Although there are various tests for mild CI, only MMSE
and neuropsychological batteries are recommended for its
early detection in Neurology Practice Parameters [39].
Fig. 3 Parameters associated with overt cognitive impairment defined by age and education corrected MMSE scores in univariate analysis with a
P value < .10. n = 525. Risk estimate and confidence limits (CL). Higher education meaning more than 10 years versus less than 10 years of formal
education. NYHA: New York Heart Association functional Class. LVEF: left ventricle ejection fraction. DM: diabetes mellitus. CKD: Chronic kidney
Disease: eGFR < 60 mL/min/1.73 m2. Anemia defined by hemoglobin < 12. COPD: chronic obstructive pulmonary disease. Nt-proBNP: N-terminal
pro Brain Natriuretic Peptide hormone. Albumin levels >3.5. Depressive symptoms: measured by Yesavage scores above 5. Family dysfunction:
Family Apgar below 7. Social support meaning lack of social support by DUKE-UNC questionnaire < 32. Frailty when Barber questionnaire above 2.
Dependency defined by Barthel test <90
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The MMSE measures general cognitive functioning, in
our study all the sub-items were lower in patients in the
advanced functional class, with the exception of registra-
tion, which is the ability to acquire the information in
the first place, and refers to short-term memory, more
influenced by unstable organic conditions [40], and are
preserved in many cognitively impaired subjects.
Clinical markers
We observed that in heart failure patients, ischemic
aetiology was linked to CI. In a recent study, lower
recall scores in cognitive tests, and cerebral grey mat-
ter loss in magnetic resonance images, were reported
in patients with ischemic heart disease compared to
non-ischemic ones [41]. Mild cerebral ischemia/hypoxia
resulting from chronic heart failure could augment the
ischemic effect and cause synaptic dysfunction, as recently
reported [42]. Hypoperfusion could be an explanation
although further research is needed to confirm this
possibility.
In concurrence with previous research we found
other factors directly linked to heart failure, as such
as NHYA advanced class, and Nt proBNP [43]. The
relationships were not, however, sustained in a multi-
variate model. LVEF was not related to CI.
Hypoalbuminemia, previously considered a mortality
predictor following myocardial infarction [44], has also
been reported to be predictive of 1 year mortality
among heart failure patients [45]. Classically linked to
frailty, in our sample, albumin levels appeared to be re-
lated to CI. We found a cutoff of 3.5 meaningful, as
levels < 3.5 were more likely associated to CI. This ef-
fect persisted after controlling for renal function and
was sustained in a regression model.
In our sample, patients under beta blocker treatment
showed less CI after adjusting for functional class, and
the effect was maintained after adjusting for multiple
factors in a regression model. In the 1990s beta-
blocker treatment was associated to cognitive impair-
ment [46, 47]. Nevertheless, recent experimental stud-
ies have suggested a protective effect [48]. Such an
effect was also observed in a retrospective study of
hypertensive patients treated with beta blockers [49]
versus other drugs.
Table 3 Psychosocial, functional and cognitive scores according to cognitive function: n = 525
Overall: 525 Normal n = 380 Cognitive impairment n = 145 n p value
Higher education 199 (38) 164 (43) 35 (24) 525 <0.001
Living with someone n % 287 (57) 217 (59) 70 (52) 504 0.098
Depressive symptoms n % 35 (7) 21 (6) 14 (10) 513 0.064
Dependency n % 206 (39) 133 (35) 73 (50) 525 0.001
Need caregiver, n (%) 127 (34) 83 (30) 44 (45) 370 0.008
Patient administer treatment n (%) 201 (60) 157 (61) 44 (47) 353 0.014
Lack of social support n % 41 (8) 27 (7) 14 (10) 515 0.282
Family dysfunction n (%) 72 (14) 50 (13) 22 (15) 520 0.325
Frailty n (%) 279 (55) 186 (50) 93 (67) 509 0.001
MMSE total age and education corrected scores mean (SD) 25 (4) 27 (2) 20 (3) 525 <0.001
MMSE orientation 9 (1) 10 (1) 8 (2) <0.001
n % task not completed 239 (45) 117 (31) 128 (83)
MMSE registration 3 (0) 3 (0) 3 (0) <0.001
n % task not completed 27 (5) 11 (3) 15 (10)
MMSE attention 3 (2) 4 (1) 2 (1) <0.001
n % task not completed 277 (53) 137 (36) 139 (96)
MMSE recall 2 (1) 2 (1) 1 (1) <0.001
n % task not completed 378 (72) 251 (66) 126 (87)
MMSE language and copying 8 (2) 8 (1) 6 (2) <0.001
n % task not completed 289 (55) 157 (41) 131 (90)
Percentages are rounded. Data are presented as numbers (with percentages) or means (standard deviation, SD), where appropriate. n represents the
number of patients with variable recorded which were analyzed for each item. Higher education defined as more than 9 years of formal education.
Depressive symptoms measured by Yesavage test >5. Dependency in daily living activities measured by Barthel test (total <20/ severe 21–60/ moderate
61–90/slight 91–99 /independence: 100. Social support by The Duke-UNC Functional Social Support Questionnaire (FSSQ), weak social support scores < 32.
Family dysfunction by APGAR index < 7; frailty when Barber self-administer questionnaire above 2 (see text) MMSE: mini-mental state examination
(Folstein [14]) corrected by age and education (Blesa [15]): cognitive impairment scores ≤24
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Gender and education
We observed that CI was more frequent in women, who
also were less educated. In the Women’s Health Initia-
tive Study [50], self-reported cardiovascular disease was
well documented as a factor that incremented the risk of
cognitive decline in postmenopausal women, particularly
in those with myocardial infarction and vascular disease
(HR 2.10; 95 % CI:1.40–3.15), whereas no association
was found with self-reported heart failure. Heart failure
of ischemic origin was associated to cognitive impair-
ment in women in our study. Further research in women
is needed to explore this relationship.
Co-morbidities
Co-morbidities, including cerebrovascular and periph-
eral arterial disease [51], must be taken in account in
CHF as they have been associated with CI and influence
avoidable hospitalization and mortality [52]. A global
assessment in CHF patients with co-morbidities illness
has been suggested [12]. We found diabetes and periph-
eral vascular disease to be associated with CI, as previ-
ously described [53, 54].
Psychosocial factors
Our study is aimed at both clinical and psychosocial
factors and we identified some that require a global
evaluation focused on practice. The identified psycho-
social factors included increased patient autonomy
(dependency level, self-reported frailty, and need of a
caregiver) which was associated with less CI. In addition,
social support is positively related to medication compli-
ance [22–24]. In our sample, as previously described in
Mediterranean countries [55], almost all the patients had
a self-perception of having a healthy social network and
satisfactory family function.
Depressive symptoms almost reached signification.
Depression was associated with poorer performance
on multiple cognitive domains in heart failure in a re-
cent study [53].
Functional limitation has emerged as a predictive
value in patients with mild CHF. [56] An elevated rela-
tionship between frailty and mortality at 12 months
follow-up has been found using the Barthel test, the
Yesavage depressive symptoms tests and a geriatric
exam [56]. We found a link between self-reported
frailty and cognitive function. Frailty and heart failure
would share a consistent correlation with some inflam-
matory biomarkers such as interleukin-6 and C-
reactive protein [57]. While there is a lack of consen-
sus on the definition of frailty, assessing it could help
tailoring treatment in selected patients. Short screen-
ing instruments such as Barber tests could be easy to
use in clinical practice. We observed that self-reported
frailty remained a stable predictor of cognitive impair-
ment in CHF patients after adjusting for clinical
variables.
Table 4 Multivariable regression model considering all significative variables (enter)
Clinical variables Model 1 Psychosocial variables Model 2 Clinical and functional Model 3
OR (95 % CI) p value OR (95 % CI) p value OR (95 % CI) p value
Gender (women) 2.98 (1.85–4.82) <0.001 2.77 (1.75–4.39) <0.001
Ischemic aetiology 1.90 (1.16–3.08) 0.010 1.99 (1.25–3.17) 0.004
Cerebrovascular disease 1.76 (0.94–3.30) 0.079
Peripheral Arterial disease 1.57 (0.91–2.73) 0.105
DM 1.15 (0.74–1.79) 0.545
Heart rate >70 1.44 (0.91–2.27) 0.118
Albumin > 3.5 0.56 (0.33–0.95) 0.030 0.59 (0.351–0.99) 0.048
eGFR 1.01 (0.64–1.58 0.965
Nt-ProBNP 1.00 (0.63–1.59) 0.990
Betablockers 0.33 (0.16–0.69) 0.003 0.36 (0.17–0.76) 0.007
Social support 0.83 (0.36–1.94) 0.668
Frailty 1.58 (1.02–2.46) 0.040 1.58 (0.99–2.50) 0.050
Family dysfunction 1.02 (0.52–1.99) 0.964
Depressive symptoms 1.72 (0.82–3.63) 0.156
Dependency 1.65 (1.08–0.53) 0.020 1.30 (0.83–2.05) 0.255
Cognitive impairment defined by MMSE age and education corrected scores
DM: Diabetis Mellitus. eGFR: estimated glomerular filtration rate. Nt-proBNP: N-terminal pro Brain Natriuretic Peptide. Social support measured by The Duke-UNC
Functional Social Support Questionnaire (FSSQ); lack of social support scores < 32. Frailty when Barber questionnaire above 2 (see text). Family dysfunction when
APGAR index < 7. Depressive symptoms measured by Yesavage test >5. Dependency in daily living activities measured by Barthel test <90. MMSE age and
education corrected scores. OR: odds ratio. CI: confidence interval. Hosmer-Lemeshow chi-square test: Model 1 p = 0.411; Model 2p = 0.766; Model 3:p = 0.713.
Nagelkerke R Square: Model 1:R2 = 0.154; Model 2: R2 = 0.052; Model 3: R2 = 0.150
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Strengths and limitations
The strengths of this study include the wide sample used,
the detailed characterization of the profiled patients, and
the multi-dimensional assessment including both clinical
and psychosocial factors. Our study has some limitations.
Its cross-sectional design implies that conclusions should
be confirmed through relevant prospective cohort studies.
In addition, from those invited to participate, 122 patients
had an incomplete evaluation and were excluded. The
excluded participants may well have had worse outcomes
or have been more impaired as they were in more ad-
vanced functional class, resulting in higher figures in our
population than reported. Moreover, education was only
recorded in 525 patients in a way that could be later
analyzed. The unregistered patients lacking education
could be also have been more impaired or have had worse
CHF markers. It might not be possible, therefore, to ex-
trapolate our results to patients with other education
levels. Furthermore, our sample only included Spanish
patients so the results may not be applicable to popula-
tions from other regions and ethnic groups.
Conclusions
The observed prevalence of cognitive impairment using
MMSE corrected scores was 27.6 %. Screening should
focus specially on patients with low albumin levels,
frailty, or heart failure of ischemic aetiology, and
women in particular. We believe that integrated care
improves results in heart failure management and facili-
tates patient monitoring focused on enhancing quality
of life. Almost one in three patients resulted impaired,
that justifies the screening in CHF patients as MMSE is
a feasible screening instrument, easy to administer on
routine settings. Identifying related factors facilitates
the selection of patients in which screening would be
especially helpful.
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